Safrin S, Sattler F R, Lee B L, Young T, Bill R, Boylan C T, Mills J
Department of Medicine, University of California, San Francisco.
J Acquir Immune Defic Syndr (1988). 1991;4(3):244-9.
In a prospective, noncomparative study, seven patients with mild Pneumocystis carinii pneumonia, characterized by room air arterial PO2 greater than 60 mm Hg at the time of presentation, were treated with dapsone alone at a dose of 200 mg daily. Two of the seven patients required mechanical ventilation for respiratory failure on day 5 of dapsone therapy; both died. Four patients experienced major side effects during dapsone therapy. None of the seven patients successfully completed a full course of therapy with dapsone. We conclude that high-dose, single-agent dapsone is not suitable for further study as therapy for Pneumocystis carinii pneumonia.
在一项前瞻性、非对照研究中，7例轻度卡氏肺孢子虫肺炎患者（表现为初诊时室内空气条件下动脉血氧分压大于60 mmHg）仅接受了每日200 mg剂量的氨苯砜治疗。7例患者中有2例在氨苯砜治疗第5天时因呼吸衰竭需要机械通气；两人均死亡。4例患者在氨苯砜治疗期间出现严重副作用。7例患者中无人成功完成氨苯砜的全程治疗。我们得出结论，高剂量单药氨苯砜不适合作为卡氏肺孢子虫肺炎治疗的进一步研究用药。
